Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
ln Vitro |
While galanide does not directly enhance K+ conductance, it does oppose the concentration-dependent rise in K+ conductance that galanin causes (IC50=4 nM). IBa, the voltage-dependent Ba2+ current, is inhibited by galandide, which functions similarly to galanin. Gallantide produces a maximal inhibition of roughly 40% of IBa, which is also concentration-dependent (IC50=16 nM) [3].
|
---|---|
ln Vivo |
In experienced male rats, intracerebroventricular injection of galanin (5 μg/rat) inhibited sexual behavior without causing any other motor or behavioral deficits. Similarly, injection of the galanin antagonist galanide (1 or 2 micrograms/rat) can both stimulate and counteract the effects of galanin on sexual behavior, increasing sexual arousal, motivation, and performance indicators [2]. Mild acute pancreatitis is improved by galantide (AP). Galantide can considerably lower AP-induced hyperenzymeemia by 41-49% [3]. When administered at doses ranging from 6–6000 nM, galantide was found to enhance social memory in the "social recognition" test [4].
|
References |
[1]. Langel U, et al. Design of chimeric peptide ligands to galanin receptors and substance P receptors. Int J Pept Protein Res. 1992;39(6):516-522.
[2]. Lindskog S, et al. The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. Eur J Pharmacol. 1992;210(2):183-188. [3]. Mulvaney JM, et al. Galantide distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons. Eur J Pharmacol. 1995;287(1):97-100 |
Molecular Formula |
C104H151N25O26S
|
---|---|
Molecular Weight |
2199.561
|
Exact Mass |
2198.0983
|
CAS # |
138579-66-5
|
Related CAS # |
Galantide TFA
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
[GWTLNSAGYLLGPQQFFGLM-NH2]
|
Synonyms |
M15; Galantide
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.4546 mL | 2.2732 mL | 4.5464 mL | |
5 mM | 0.0909 mL | 0.4546 mL | 0.9093 mL | |
10 mM | 0.0455 mL | 0.2273 mL | 0.4546 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.